Abstract Library

#2179 Exploring Nutrition Screening and Management Practices amongst Health Professionals Managing Patients with Neuroendocrine Tumors

Introduction: Patient’s with neuroendocrine tumours (NET) are at nutritional risk due to symptoms and side-effects of treatment. Current evidence based guidelines lack information regarding optimal nutritional management and supportive care.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kennedy E

Authors: Kennedy E, Kiss N, Michael M, Gough K, Drosdowsky A,

Keywords: neuroendocrine, health professional, nutrition, symptoms, malnutrition,

#1885 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor

Introduction: Patients with a neuroendocrine tumour (NET) frequently experience physical and psychosocial complaints. Novel strategies to provide information to optimize supportive care in these patients are of interest.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: de Hosson L

Authors: De Hosson L, Bouma G, Van Essen H, De Bock G, De Groot D,

Keywords: neuroendocrine tumor, information, quality,

#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study

Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67<10%) NETs, but prospective data on SSAs in advanced lung NETs are lacking.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D,

Keywords: Lung NETs, lanreotide,

#1502 Impact of Prior Chemotherapy (Chemo) on Progression-free Survival (PFS) in Patients (Pts) with Advanced, Nonfunctional Lung or Gastrointestinal (GI) Neuroendocrine Tumors (NET): A Secondary Analysis from the Phase 3 RADIANT-4 Study.

Introduction: In the phase 3 RADIANT-4 study, everolimus (EVE) improved PFS by 7.1 months (mo) compared to placebo (PBO; P<0.00001) in pts with advanced, progressive, nonfunctional NET of lung or GI tract.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Pommier R

Authors: Pommier R, Strosberg J, Singh S, Wolin E, Yao J,

Keywords: Everolimus, nonfunctional NET, prior chemotherapy,

#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study

Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Fazio N

Authors: Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E,

Keywords: PFS, Everolimus, Lung carcinoid,